

## DNB FUND HEALTH CARE A (ACC) EUR

ISIN: LU1660425346. BLOOMBERG TICKER: DNBHCAC LX. WKN: A2DVRC


### Fund Objective and Policy

This equity fund aims to maximise long-term returns on the fund's investments without taking undue risk.

The fund invests in equities of companies within healthcare, pharmaceuticals, medical devices, biotechnology and related industries, listed on stock exchanges and regulated markets worldwide.

The fund is actively managed. Investment decisions are based on long-term fundamental analysis, including in-depth assessment of companies, markets and other factors that may affect corporate performance.

### Fund vs. index performance



Past performance does not predict future returns.

Source: DNB Asset Management

### Performance (% net of fees)

Cumulative Return (%)	YTD	MTD	1 year	3 years	5 years	10 years	Since launch
Fund	-0.02	1.20	-1.90	11.01	45.96	-	76.68
Index	3.47	3.67	-1.36	17.09	48.50	-	103.88

Annualised Return (%)	3 years	5 years	10 years	Since launch
Fund	3.54	7.85	-	7.02
Index	5.40	8.23	-	8.87

Calendar Year (%)	2025	2024	2023	2022	2021	2020	2019	2018	2017	-
Fund	4.16	4.98	-0.83	2.93	29.89	-8.28	21.59	9.56	-0.24	-
Index	1.24	7.88	0.24	0.79	28.90	4.14	25.51	7.68	-1.58	-

Source: DNB Asset Management

### Performance disclaimer

The performance quoted is past performance and is not a guarantee of future returns. Future returns will e.g. depend on market developments, the manager's skill, the fund's risk, as well as the costs of subscription, management and redemption. The principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than the original cost. Current performance: [www.dnbam.com](http://www.dnbam.com)



**Rune Sand-Holm**  
(Lead portfolio manager)

- **Benedicte Kilander Bakke**  
(Portfolio Manager)
- **Anesa Mulabecirovic Sahnoun**  
(Analyst)

### Fund information

Legal status	UCITS SICAV
Domicile	Luxembourg
Share class inception date	2017-10-10
Fund inception date	2017-10-02
Asset class	Equity fund
Share class NAV	EUR 17.67
Share class (AuM)	EUR 0.28 million
Fund (AuM)	EUR 112.63 million
Investment process	Fundamentally driven management
Market focus	Across regions
Industry focus	Health care
Liquidity focus	Large to medium sized companies
Fund index	MSCI World Health Care Index
Use of income	Accumulating

Source: DNB Asset Management

### SRI



Lower risk

Higher risk

#### Risk indicator

Summary risk indicator from 1 (lowest risk) to 7 (highest). Risk 1 is not equal to a risk-free investment. This indicator can change from time to time.

### Risk information

	Fund	Index	Rel.
Number of companies	38	118	80
Alpha*			-1.76%
Beta*			1.02
Information Ratio*			-0.49
Max drawdown	-25.06%	-26.64%	
Sharpe Ratio*	0.02	0.16	
Tracking Error*			3.77%
Volatility*	13.77%	13.04%	

Source: DNB Asset Management

\* These figures are calculated 3 years rolling based on weekly return series.

### Conditions

Minimum subscription	EUR 0
Liquidity	Daily
Cut-off*	13:00 CET
Swing pricing	Yes
Management fee**	1.50%
Performance fee	10% of excess performance
Subscription fee	maximum 5%
Redemption fee	None
Recommended holding period	7 years

\* Same day as valuation day.

\*\* Per annum

Source: DNB Asset Management

## DNB FUND HEALTH CARE A (ACC) EUR

ISIN: LU1660425346. BLOOMBERG TICKER: DNBHCAC LX. WKN: A2DVRC

### Top 10 biggest portfolio positions\*

Name	Country	Sector	%
Eli Lilly & Co	United States	Health Care	8.45
AstraZeneca Plc	United Kingdom	Health Care	6.92
Roche Holding AG	Switzerland	Health Care	6.75
Merck & Co Inc	United States	Health Care	4.62
AbbVie Inc	United States	Health Care	4.59
UnitedHealth Group Inc	United States	Health Care	3.90
Novo Nordisk AS	Denmark	Health Care	3.87
Sanofi SA	France	Health Care	3.71
Dexcom Inc	United States	Health Care	3.59
Abbott Laboratories	United States	Health Care	3.56

### Top 5 relative overweight (YTD)\*

Name	Sector	Sub-Sector	%
Dexcom Inc	Health Care	Health Care Equipment & Services	3.33
AstraZeneca Plc	Health Care	Pharmaceut. Biotechn. & Life Sciences	3.03
Roche Holding AG	Health Care	Pharmaceut. Biotechn. & Life Sciences	2.75
Siemens Healthineers AG	Health Care	Health Care Equipment & Services	2.65
Novo Nordisk A/S	Health Care	Pharmaceut. Biotechn. & Life Sciences	2.46

### Top 5 relative underweight (YTD)\*

Name	Sector	Sub-Sector	%
Johnson & Johnson	Health Care	Pharmaceut. Biotechn. & Life Sciences	-4.17
Novartis AG	Health Care	Pharmaceut. Biotechn. & Life Sciences	-3.80
Amgen Inc	Health Care	Pharmaceut. Biotechn. & Life Sciences	-2.47
Gilead Sciences Inc	Health Care	Pharmaceut. Biotechn. & Life Sciences	-2.15
Pfizer Inc	Health Care	Pharmaceut. Biotechn. & Life Sciences	-1.86

### Top 5 relative contributors (YTD)\*

Name	Sector	Sub-Sector	%
Boston Scientific Corp	Health Care	Health Care Equipment & Services	0.40
AstraZeneca Plc	Health Care	Pharmaceut. Biotechn. & Life Sciences	0.30
Roche Holding AG	Health Care	Pharmaceut. Biotechn. & Life Sciences	0.29
EssilorLuxottica SA	Health Care	Health Care Equipment & Services	0.23
Dexcom Inc	Health Care	Health Care Equipment & Services	0.22

### Top 5 relative detractors (YTD)\*

Name	Sector	Sub-Sector	%
Novo Nordisk A/S	Health Care	Pharmaceut. Biotechn. & Life Sciences	-0.96
Novartis AG	Health Care	Pharmaceut. Biotechn. & Life Sciences	-0.59
Johnson & Johnson	Health Care	Pharmaceut. Biotechn. & Life Sciences	-0.57
Amgen Inc	Health Care	Pharmaceut. Biotechn. & Life Sciences	-0.32
Gilead Sciences Inc	Health Care	Pharmaceut. Biotechn. & Life Sciences	-0.32

### Sector breakdown (%)\*

Pharmaceut. Biotechn. & Life Sciences	69.39
Health Care Equipment & Services	29.80

### Country breakdown (%)\*

United States	65.12
Switzerland	9.67
United Kingdom	6.92
Denmark	5.09
Belgium	4.31
France	3.71
Germany	2.80
Canada	1.57

### Currency breakdown (%)\*

USD	66.72
EUR	10.87
CHF	10.02
GBP	7.30
DKK	5.12
SEK	0.00
HUF	0.00
JPY	0.00

### Market cap breakdown (%)\*

> 10bn USD	49.98
> 200bn USD	41.72
> 5bn USD	4.91
> 1bn USD	2.58
Others	0.00
< 1bn USD	0.00
Derivative	0.00
FX derivative	0.00

\*Source: DNB Asset Management  
Dynamic portfolio: Allocations may vary over time.  
Based on holdings as at 27.02.2026.

## DNB FUND HEALTH CARE A (ACC) EUR

ISIN: LU1660425346. BLOOMBERG TICKER: DNBHCAC LX. WKN: A2DVRC

### SFDR - Article 8

The fund promotes, in addition to other considerations, environmental and social aspects through its investment strategy.

### ESG approaches

ESG integration	Yes
Voting	Yes
Exclusions	Yes
Dialogues	Yes
Inclusions	No
Thematic	No

Source: DNB Asset Management

### Exclusion criteria (negative screening)

In addition to norm-based exclusions, the fund does not invest in companies that operate within:

- Controversial weapons
- Tobacco (production)
- Pornography (production)
- Cannabis for recreational use
- Coal  $\geq$  30% of revenues + Absolute criterion
- Oil sands  $\geq$  30% of revenues

[DNB's instructions for responsible investments](#)

[Excluded companies](#)

### Sustainability indicator

The fund promotes, in addition to other considerations, environmental and social aspects through its investment strategy.

### Sustainability data

	Fund	Index*
ESG score (from 1 to 10)	6.53	6.83
Carbon intensity	14.61	12.49

Source: MSCI ESG Research and internal assessments.  
2025 MSCI ESG Research LLC. Reproduced by permission.  
Based on holdings as at 2026-02-27.  
\*MSCI World Health Care Index

### Voting

One way to positively influence companies is through voting at general meetings. Our voting guidelines require us to vote at all general meetings of all Norwegian companies in which we have investments. We have chosen a systematic approach to determining which international companies' general meetings we will vote at.

### Standard setting

Standard setting is an important element of active ownership. As part of this, we develop and publish expectation documents within important areas, which we use to contribute to the improvement of standards in the market, and to form the basis of engagements with companies.

### International Norms and standards

ESG data is integrated into our portfolio management system and is used to assess risks and opportunities related to ESG in investment decisions.



### Dialogues

We engage in dialogue with companies. The dialogue can address specific ESG issues (reactive dialogue), or more generally help influence companies in a more sustainable direction (proactive dialogue).

The detailed Responsible Investment Policy and the Corporate Exclusion List are available at: <https://dnbam.com/en/responsible-investments/esg-overview-dnb-funds>



Water



Anti corruption



Climate change



Environment



Human rights



Tax



Gender equality



Oceans



Biodiversity

### MSCI ESG Research Ltd

Although DNB Asset Management's information providers, including without limitation, MSCI ESG Research LLC and its affiliates (the 'ESG Parties'), obtain information (the 'Information') from sources they consider reliable, none of the ESG Parties warrants or guarantees the originality, accuracy and/or completeness, of any data herein and expressly disclaim all express or implied warranties, including those of merchantability and fitness for a particular purpose. The Information may only be used for your internal use, may not be reproduced or disseminated in any form and may not be used as a basis for, or a component of any financial instruments or products or indices. Further, none of the Information can in and of itself be used to determine which securities to buy or sell or when to buy or sell them. None of the ESG Parties shall have any liability for any errors or omissions in connection with any data herein, or any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages.

The decision to invest in the sub-fund should consider all the characteristics as described in the Prospectus and Key Information Document (KID). The documents are available on [www.dnbam.com](http://www.dnbam.com) under section "Our funds", DNB Asset Management AS at Dronning Eufemias gate 30, 0021 Oslo Norway, or the management company FundPartner Solutions (Europe) S.A at 15, avenue John F. Kennedy, L-1855 Luxembourg.

Disclaimer: Values may vary over time.

## DNB FUND HEALTH CARE A (ACC) EUR

ISIN: LU1660425346. BLOOMBERG TICKER: DNBHCAC LX. WKN: A2DVRC

### Risk considerations (Generally speaking, every investment presents a risk of loss of capital.)

#### Company risk

The risk that something will happen to one or more companies in which the fund have invested causing those investments to lose value

#### Concentration risk

The risk that a negative event or shift in a particular sector or geography to which the fund's investments are exposed causing those investments to lose value

#### Systematic risk

The risk that e.g. an economic shocks or political instability in the market in which the fund invests causing all of the fund's investments to lose value

#### Liquidity risk

The risk that one or more of the fund's investments could become hard to value, or to sell at a desired time and price

#### Currency risk

The risk that a negative change in a currency to which the fund is exposed causing these currency denominated investments to lose value

Further investment risks are set out in the risk warnings chapter in the prospectus.

## Glossary

#### Alpha

Alpha shows the percentage performance of a fund above or below that explained by its exposure to the broader market.

#### Beta

Beta shows the average extent a fund's return moves relative to the broader market. A fund with a beta above 1 moves on average more than the market and below 1 moves on average less than the market.

#### Cut-off

Deadline for remittance of orders to the transfer agent in Luxembourg as set out in the relevant annexes to the prospectus. You may be required to submit your orders to your financial advisor or fund distributor by an earlier cut-off time.

#### Correlation and annualised volatility

Correlation shows how a fund's return moves in relation to the benchmark. Highly correlated investments tend to move up and down together while this is not true for investments with low correlation. Standard deviation or annualised volatility is a measure of historical volatility. It is calculated by comparing the average return with the average variance from that return.

#### Inception date

The inception date is the date taken into account for the start of performance calculation. On the launch date, all assets were transferred to the current sub-fund in exchange for shares of the current sub-fund.

#### Maximum drawdown

The largest loss measured from peak to trough until a new peak is attained.

#### NAV

An acronym of net asset value.

#### Ongoing charges (OCR)

Ongoing charges are based over 12 months of expenses ending the 31 December of the previous year. It is annually updated, but may be adjusted more frequently.

#### Sharpe ratio

The Sharpe ratio shows the fund's risk-adjusted performance. It is calculated by dividing the excess return (portfolio return minus risk free return) by the volatility.

#### SRI

The Summary Risk Indicator is a guide to the level of risk of this product compared to other products. The risk of the product may be significantly higher if held for less than the recommended holding period.

#### Standard deviation

Standard deviation or annualised volatility is a measure of historical volatility. It is calculated by comparing the average return with the average variance from that return.

#### Swing pricing

Swing pricing is an anti-dilution technique which protects long term investors from the direct and indirect costs of capital activities in the fund. The long-term performance of the fund is maintained with this solution.

#### Tracking error

The volatility of the fund's excess returns over its benchmark returns. It quantifies how closely a manager's return pattern follows that of the benchmark.

## Marketing Communication / Important Information

This document constitutes a marketing communication. Investors should read the **prospectus, Key Information Document (KID), semiannual and annual reports, and summary of investor rights** before making any investment decision. English versions are available at [www.dnbam.com](http://www.dnbam.com) under "Our Funds", at **DNB Asset Management AS**, Dronning Eufemias gate 30, 0021 Oslo, Norway, or at the management company **FundPartner Solutions (Europe) S.A.**, 15, avenue John F. Kennedy, L-1855 Luxembourg. Local language versions may also be available.

Not all funds or fund units are available for sale in all countries. This material is not directed to, nor intended for use by, any person or entity in a jurisdiction where distribution would be unlawful. Tax treatment depends on individual circumstances and may change over time. References to rankings, ratings, or awards are not guarantees of future performance. Investments in funds carry financial risk. Note: Investing in the Fund involves

acquiring units or shares of the Fund, not the underlying holdings.

**Issuer:** DNB Asset Management AS, authorised and regulated by **Finanstilsynet**, Norway, and part of DNB Group.

**Switzerland:** Representative: FundPartner Solutions (Switzerland) S.A., Route des Acacias 60, CH-1211 Geneva 73. Paying Agent: Banque Pictet & Cie SA, Route des Acacias 60, CH-1211 Geneva 73.

**USA:** Fund units may not be offered, sold, or transferred in the United States.

**UK:** This document constitutes a financial promotion under Section 21 of the UK Financial Services and Markets Act 2000 (as amended) and was approved by Carne International Financial Services (UK) Limited, authorised and regulated by the FCA. UK investors

cannot refer complaints against the Management Company or Depositary to the UK Financial Ombudsman Service, nor are losses covered by the Financial Services Compensation Scheme. Complaints may be made to the SICAV, Management Company, or Operator/Depositary via the CSSF if the CSSF's conditions for out-of-court complaints are met. UK investors may contact DNB Bank ASA for guidance on complaints or alternative dispute resolution.

#### Investor Rights Summary (English):

**DNB SICAV (LU-Funds):** <https://www.pictet.com/content/dam/www/documents/legal-and-notes/fundpartner-solutions/fps-summary-of-Investors-rights.pdf>.coredownload.pdf

No part of this material may be copied or redistributed without prior written consent from DNB Asset Management AS.